Ludwig Enterprises (Ludwig Enterprises) Total Receivables : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Total Receivables?

Ludwig Enterprises's Total Receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Ludwig Enterprises Total Receivables Historical Data

The historical data trend for Ludwig Enterprises's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Total Receivables Chart

Ludwig Enterprises Annual Data

Trend

Dec22

Dec23

Total Receivables

Ludwig Enterprises Quarterly Data
	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Ludwig Enterprises Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Ludwig Enterprises Total Receivables Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ludwig Enterprises (Ludwig Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431

Website

https://www.ludwigent.com

Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.